Biotech's $556M Double IPO Has Wall Street Feeling Something

Hemab's first day of trading told the real story, though. Shares opened at $27 (a 50% pop) and closed at $34, nearly doubling from the IPO price. That kind of debut screams institutional confidence.

Seaport Therapeutics (Nasdaq: SPTX) plays in a completely different arena: the brain. The company develops oral medicines for neuropsychiatric conditions like major depression and PTSD using something called the Glyph platform, a technology that helps drugs survive the journey through your liver without getting destroyed or causing toxicity. It's like giving a medicine a bulletproof vest for the most dangerous part of its trip through your body.

Seaport raised $254.9 million after upsizing from an initial target of 11.8 million shares to 14.2 million. Their lead program, SPT-300, is in a Phase 2b trial for major depressive disorder with top-line data expected in 2027. A second candidate, SPT-320, is a cleverly redesigned version of an antidepressant (agomelatine) that works in Europe but was never approved in the U.S. because of liver safety concerns. Seaport's Glyph technology is designed to sidestep that problem entirely.

This was the first neuro-focused biotech IPO of 2026, a milestone that matters because brain drugs have historically been one of the hardest sells to public market investors. The failure rate in CNS (central nervous system) drug development is notoriously high, making Seaport's ability to raise a quarter billion dollars all the more impressive.

The Team That Keeps Winning

Seaport's founding pedigree helps explain the investor enthusiasm. CEO Daphne Zohar and board chair Steven Paul were part of the team behind Karuna Therapeutics, which developed a novel antipsychotic called Cobenfy and was acquired by Bristol Myers Squibb for $14 billion in 2024. Board member Sharon Mates co-founded Intra-Cellular Therapies, maker of the schizophrenia drug CAPLYTA; Johnson & Johnson bought that company for $14.6 billion in 2025.

Two exits worth a combined $28.6 billion across the leadership team? That's not a résumé. That's a cheat code.

Zohar has been vocal about Seaport's decision to go public rather than sell. "We're very committed to these programs," she said, adding that the IPO proves "a clear path for companies to advance their medicines on their own." In a market where M&A has been the default exit strategy, that's a notable stance.

What This Signals for the Rest of 2026

These two IPOs didn't happen in a vacuum. They're part of a broader thaw in biotech capital markets that's been building all year. Kailera Therapeutics raised $719 million in its IPO. Generate:Biomedicines pulled in $400 million. Eikon Therapeutics grabbed $381 million. The deals keep getting bigger.

But the market isn't just throwing money at anything with a lab coat. Analysts describe the 2026 environment as "more discerning": investors want later-stage clinical data, capital-efficient business models, and credible management teams. Both Hemab and Seaport checked all three boxes.

Antoine Papiernik, managing partner and chairman at Sofinnova Partners (a lead investor in Hemab's pre-IPO Series C), captured the mood well: "As the market continues to perform, we should see more companies pursuing the IPO route, including smaller offerings and potentially earlier-stage or higher-risk opportunities."

Translation: the door is open, and it might be getting wider.

The Bigger Picture

The supporting numbers tell a consistent story. Venture funding reached $5.2 billion in Q1. Licensing deals totaled a staggering $82.7 billion in announced value in Q1 2026. Capital is flowing into biotech from every direction.

None of this guarantees success for Hemab or Seaport, of course. Hemab has zero revenue and posted a $63.9 million net loss last year. Seaport's lead drug won't have pivotal data for at least another year. Pre-revenue biotech investing is, by nature, a bet on science that hasn't been fully proven yet.

But the fact that public investors are willing to write $556 million in checks for two clinical-stage companies, in two very different therapeutic areas, on the same week? That tells you something about where sentiment stands. After years of caution, biotech's public markets are breathing again. And based on the early returns (looking at you, Hemab's 89% first-day pop), investors seem pretty happy to be back.

Your Liver Might Be the Secret Weapon Against Alzheimer's

Researchers delivered a protective gene to mouse livers and watched amyloid plaques shrink in their brains. No blood-brain barrier crossing required. This peripheral approach could rewrite the Alzheimer's treatment playbook.